Business Highlights during the fourth quarter 2023
- Encouraging preclinical data using uTREAT in non-small cell lung cancer
- Announcing the submission of the clinical trial application to the
European Medicines Agency for the investigation of uTRACE in a phase 2 trial - Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress
"We had a busy quarter, announcing key data for uTREAT in non-small lung cancer as we continue to validate our theranostics approach for improved diagnosis and treatment of certain cancers." Stated
Q4 (2023-10-01 - 2023-12-31)
- Gross loss amounted to kDKK -5,493 (kDKK -3,792)
- Operating loss amounted to kDKK -7,907 (kDKK -7,066)
- Loss before tax amounted to kDKK -7,892 (kDKK -7,095)
- Loss for the period amounted to kDKK -6,413 (kDKK -6,810)
- Total assets amounted to kDKK 38,742 (kDKK 59,667)
- Equity ratio amounted to 81,0% (96,5%)
-
Earnings per share amounted to
DKK -0,32 (DKK -0,34 )
Q1-Q4 (2023-01-01 - 2023-12-31)
- Gross loss amounted to kDKK -25,729 (kDKK -11,488)
- Operating loss amounted to kDKK -33,214 (kDKK -18,862)
- Loss before tax amounted to kDKK -33,220 (kDKK -19,488)
- Loss for the year amounted to kDKK -26,169 (kDKK -18,349)
- Total assets amounted to kDKK 38,742 (kDKK 59,667)
- Equity ratio amounted to 81,0% (96,5%)
-
Earnings per share amounted to
DKK -1,32 (DKK -0,92 )
For more information regarding
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
https://news.cision.com/curasight/r/year-end-report-october---december-2023,c3933531
https://mb.cision.com/Main/19744/3933531/2621085.pdf
(c) 2024 Cision. All rights reserved., source